Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Report: Carlyle in Talks to Buy PPD

By Pharmaceutical Processing | August 16, 2011

 

NEW YORK (AP) — Private-equity firm Carlyle Group is in
talks to acquire contract drug developer Pharmaceutical Product Development
Inc., according to a report published Monday.

Carlyle has edged out several other private-equity firms and
entered into exclusive talks with the Wilmington,
N.C. drug maker, according to
Bloomberg News, which cited five unnamed persons with knowledge of the
discussions.

Blackstone Group LP, KKR & Co., and Hellman &
Friedman LL were among the other firms that were interested in buying the PPD,
according to the report.

Most of the bids amounted to as much as $4.3 billion,
according to the report.

Carlyle is speaking to other private-equity firms about
joining its bid for PPD, though its talks with PPD could still collapse, the
report said.

A spokesman for Pharmaceutical Product Development declined
to comment Monday. A call to Carlyle was not immediately returned.

Last month, Pharmaceutical Product Development said its
board of directors had asked management to review its strategy and capital
structure, and that it would look for any actions it can take that will create
value for shareholders.

The company, which has a market cap of $3.5 billion, provides
contract drug development and discovery services for pharmaceutical,
biotechnology, medical device, academic and government organizations. It has
offices in 44 countries and more than 11,000 employees.

PPD shares ended the regular session up $4.91, or 18.5
percent, at $31.51. They tacked on another $2.01, or 6 percent, to $33.52 in
extended trading.

 

Related Articles Read More >

A Zipline fixed-wing drone in the air drops a package
Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
Pfizer logo
Pfizer to spend $120M to make COVID-19 oral treatment in U.S.
Image of MedTrace Pharma's P3 automated delivery system for 15-O water in action
MedTrace Pharma moves forward on 15 O-water imaging tech
coronavirus COVID-19 Pfizer
NIH starts evaluating second COVID-19 booster shots in adults

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards